Sunitinib for advanced renal cell cancer

Biologics: Targets and Therapy

Volumn 2, Issue 1, 2008, Pages 97-106

  Coppin, Chris ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Renal cell cancer; Sunitinib; Targeted therapy

Indexed keywords

EID: 50249173332     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: 10.2147/btt.s1834     Document Type: Review

References (60)

1. Abrams TJ, Lee LB, Murray LJ, et al. 2003. SU11248 inhibits KIT and platelet-derived growth factor receptor â in preclinical models of human small cell lung cancer. Mol Cancer Ther, 2:471-478.
2. Amato RJ, Harris P, Dalton M, et al. 2007. A phase II trial of intra-patient dose-escalated sorafenib in patients with metastatic renal cell cancer. J Clin Oncol, 25(18S) ASCO Proc:5026.
3. Atkins MB. 2007. Molecularly targeted therapy for advanced renal cell carcinoma. UpToDate [online]. Accessed 15 Aug 2007. URL: www. uptodate.com.
4. Bello CL, Garrett M, Smerglia J, et al. 2006. Pharmacokinetics of sunitinib malate (SU11248) in subjects with hepatic impairment. Annals Oncol, 17 (S9) ESMO Proc:451P.
5. Chow LQM, Eckhardt SG. 2007. Sunitinib: from rational design to clinical efficacy. J Clin Oncol, 25:884-96.
6. Chowdhury S, Spicer JE, Harper PG. 2006. Hypertension and targeted therapy. Part 2: small molecule inhibitors of VEGF. Targeted Oncol, 1:172-8.
7. Coppin C, Porzsolt F, Autenrieth M, et al. 2004. Immunotherapy for advanced renal cell cancer (review).type=journal>Cochrane Database of Systematic Reviews 2004, Issue 2. Wiley.
8. Coppin C, Le L, Porzolt F, et al. 2008. Targeted therapy for advanced renal cell carcinoma (review). Cochrane Database of Systematic Reviews 2008, Issue 2. In press.
9. Demetri GD, van Oosterom AT, Garrett CR, et al. 2006. Effi cacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomized controlled trial. Lancet, 368:1329-1338.
10. Desai J, Yassa L, Marqusee E, George S, et al. 2006. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors.Ann Intern Med, 145:660-4.
11. Dutcher JP, Szczylik C, Tannir N, et al. 2007. Correlation of survival with tumor histology, age, and prognostic risk group for previously untreated patients with advanced renal cell carcinoma receiving temsirolimus or interferon alpha. J Clin Oncol, 25(18S) ASCO Proc:5033.
12. Eddy DM. 1994. Principles for making diffi cult decisions in diffi cult times. JAMA, 271:1792-8.
13. Elaraj DM, White DE, Steinberg SM, et al. 2004. A pilot study of antiangiogeneic therapy with bevacizumab and thalidomide in patients with metastatic renal cell carcinoma. J Immunother, 27:259-64.
14. Escudier B, Eisen T, Stadler WM, et al. 2007a. Sorafenib in advanced clearcell renal-cell carcinoma. N Engl J Med, 356:125-34.
15. Escudier B, Koralewski P, Pluzanska A, et al. 2007b. A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-a2a vs placebo/interferon-a2a as fi rst-line therapy in metastatic renal cell carcinoma. J Clin Oncol, 25(18S) ASCO Proc:3.
16. Faivre S, Delbaldo C, Vera K, et al. 2006. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol, 24:25-35.
17. Fyfe GA, Fisher RI, Rosenberg SA, et al. 1996. Long term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy. J Clin Oncol, 14:2410.
18. Garber K. 2003. Sugen falls as casualty of Pfi zer-Pharmacia merger. Nat Biotechnol, 21:722-3.
19. George DJ, Michaelson MD, Rosenberg JE, et al. 2007. Phse II trial of sunitinib in bevacizumab-refractory metastatic renal cell carcinoma: updated results and analysis of circulating biomarkers. J Clin Oncol, 25(18S) ASCO Proc:5035.
20. Gleave ME, Elhilali M, Fradet Y, et al. 1998. Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. N Engl J Med,338:1265-71.
21. Goffi n J, Baral S, Tu D, et al. 2005. Objective responses in patients with malignant melanoma or renal cell cancer in early studies do not predict regulatory approval. Clin Cancer Res, 11:5928-34.
22. Goodman VL, Rock EP, Dagher R, et al. 2007. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res,13:1367-73.
23. Gordon MS, Manola J, Fairclough D, et al. 2004. Low dose interferon-a2b+ thalidomide in patients with previously untreated renal cell cancer.Improvement in progression-free survival but not quality of life or overall survival. A phase III study of the Eastern Cooperative Oncology Group (E2898). J Clin Oncol, 22(14S) ASCO Proc:4516.
24. Gore ME, Porta C, Oudard S, et al. 2007. Sunitinib in metastatic renal cell carcinoma: preliminary assessment of toxicity in an expanded access trial with subpopulation analysis. J Clin Oncol, 25(18S) ASCO Proc:5010.
25. Hanagan D, Weinberg RA. 2000. The hallmarks of cancer. Cell, 100:57-70. *Houk BE, Bello CL, Michaelson MD, 2007. Exposure-response of sunitinib in metastatic renal cell carcinoma: a population pharmacokinetic/ pharmacodynamic approach. J Clin Oncol, 25(18S) ASCO Proc:15572.
26. Hudes G, Carducci M, Tomczak P, et al. 2007. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med,356:2271-81.
27. Kerbel R, Folkman J. 2002. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer, 2:727-39.
28. Kollmannsberger CK, Heng DY, Murray N, et al. 2007. A population-based study evaluating metastatic renal cell cancer patients treated with interferon (IFN) alone, fi rst-line IFN then second-line sunitinib, or sunitinib alone. J Clin Oncol, 25(18S) ASCO Proc:15572.
29. Linehan WM, Grubb RL, Coleman JA, et al. 2005. The genetic basis of kidney cancer: implications for gene-specifi c clinical management. BJU Int, 95(S2):2-7.
30. Manning G, Whyte DB, Martinez R, et al. 2002. The protein kinase complement of the human genome. Science, 298:1912-34.
31. McDermott DF, Regan MM, Clark JI, et al. 2005. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol, 23:133-41.
32. Mendel DB, Laird AD, Xin X, et al. 2003. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.Clin Cancer Res, 9:327-37.
33. Mickisch GHJ. 2003. Rational selection of a control arm for randomized trials in metastatic renal cell carcinoma. Eur Urol, 43:670-9.
34. Moss KG, Toner GC, Cherrington JM, et al. 2003. Hair depigmentation is a biological readout for pharmacological inhibition of KIT in mice and humans. J Pharmacol Exp Ther, 307:476-480.
35. MRC Renal Cancer Collaborators. 1999. Interferon-alpha and survival in metastatic renal cell carcinoma: early results of a randomized controlled trial. Lancet, 353:14-17.
36. Motzer RJ, Bacik J, Murphy BA, et al. 2002. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol, 20:289-96.
37. Motzer RJ, Bacik J, Schwartz LH, et al. 2004. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma.J Clin Oncol, 22:454-463.
38. Motzer RJ, Michaelson D, Redman BG, et al. 2006a. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol, 24:16-24.
39. Motzer RJ, Rini BI, Bukowski RM, et al. 2006b. Sunitinib in patients with metastatic renal cell carcinoma. JAMA, 295:2516-24.
40. Motzer RJ, Hutson TE, Tomczak P, et al. 2007a. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med, 356:115-24.
41. Motzer RJ, Figlin RA, Hutson TE, et al. 2007b. Sunitinib versus interferonalfa as fi rst-line treatment of metastatic renal cell carcinoma: updated results and analysis of prognostic factors. J Clin Oncol, 25(18S) ASCO Proc:5024.
42. Na X, Wu G, Ryan CK, et al. 2003. Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1〈 expression in renal cell carcinomas. J Urol, 170:588-92.
43. Negrier S, Perol D, Ravaud A, et al. 2005. Do cytokines improve survival in patients with metastatic ernal cell carcinoma of intermediate prognosis? Results of the prospectively randomized PERCY Quattro trial. J Clin Oncol, 23(16S) ASCO Proc:4511.
44. Oliver RTD, Nethersell ABW, Bottomley JM. 1989. Unexplained spontaneous regression and alpha-inerferon as treatment for metastatic renal carcinoma. Br J Urol, 63:128-31.
45. Osusky KL, Hallahan DE, Fu A, et al. 2004. The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels. Angiogenesis, 7:225-33.
46. Pyrhonen S, Salminen E, Ruutu M, et al. 1999. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol, 17:2859-67.
47. Ratain MJ, Eckhardt SG. 2004. Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST. J Clin Oncol, 22:4442-5.
48. Ratain MJ, Eisen T, Stadler WM, et al. 2006. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol, 24:2505-12.
49. Remak E, Mullins CD, Akobundu E, et al. 2007. Economic evaluations of sunitinib versus interferon-alfa in fi rst-line metastatic renal cell carcinoma. J Clin Oncol, 25(18S) ASCO Proc:6607.
50. Rini BI, Small EJ. 2005. Biology and clinical dvelopment of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. type=journal>J Clin Oncol, 23:1028-1043.
51. Rini BI, Campbell SC. 2007. The evolving role of surgery for advanced renal cell carcinoma in the era of molecular targeted therapy. J Urol,177:1978-84.
52. Srinivas S, Roigas J, Gillessen S, et al. 2007. Continuous daily administration of sunitinib in patients with cytokine-refractory metastatic renal cell carcinoma: updated results. J Clin Oncol, 25(18S) ASCO Proc:5040.
53. Stadler W. 2007a. Chromosomes, hypoxia, angiogenesis, and trial design: a brief history of renal cancer drug development. Clin Cancer Res,13:1630-3.
54. Stadler WM. 2007b. The randomized discontinuation trial: a phase II design to assess growth-inhibitory agents. Mol Cancer Ther, 6:1180-5.
55. Sun L, Liang C, Shirazian S, et al. 2003. Discovery of 5-[5-fl uoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J Med Chem, 46:1116-19.
56. Szczylik C, Demkow T, Staehler M, et al. 2007. Randomized phase II trial of fi rst-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: fi nal results. J Clin Oncol, 25(18S)ASCO Proc:5025.
57. Therasse P, Arbuck SG, Eisenhauer EA, et al. 2000. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst, 92:205-16.
58. Vogelzang NJ, Sternberg CN. 2007. Signal-transduction inhibitors in renal cell carcinoma. BJU Int, 99:1289-95.
59. Wright JC, Weinstein MC. 1998. Gains in life expectancy from medical interventions - standardizing data on outcomes. N Engl J Med,339:380-6.
60. Zia MI, Siu LL, Pond GR, et al. 2005. Comparison of outcomes of phase II studies and subsequent randomized control studies using identical chemotherapeutic regimens. J Clin Oncol, 23:6982-91.